Blood cancer Clinical Trials in Boston, MA

As of September 2026, 139 paid clinical trials are recruiting for Blood cancer in Boston, Massachusetts. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: September 1, 2026.

Filter results

State

City

Facility

Recruitment status

Phase

Study type

Intervention

Condition

Sex

Age

Healthy volunteers only

140 clinical trials for Blood cancer

·Clear filters·

Email me when a new blood cancer trial opens in Boston, MA.

A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis

for Myelofibrosis

Drug: Ruxolitinib

Sites in Boston +8 more locations

Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All·Age: 18+

Code: NCT06773195·Phase 1, Phase 2·Recruiting·Listed Jan 2025

Apply to this trial

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

for Acute Biphenotypic Leukemia

Sites in Boston +7 more locations

Sponsor: Fred Hutchinson Cancer Center

Sex: All·Age: 6 Months - 26·Accepts healthy volunteers

Code: NCT03779854·Phase 2·Recruiting·Listed Dec 2018

Apply to this trial

Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)

for Blood Cancer

1 location in Boston

Sponsor: Dana-Farber Cancer Institute

Sex: All·Age: 18+·Accepts healthy volunteers

Code: NCT06469307·Recruiting·Listed Jun 2024

Apply to this trial

Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

for High-risk Smoldering Multiple Myeloma

Sites in Boston +2 more locations

Sponsor: Irene Ghobrial, MD

Sex: All·Age: 18+

Code: NCT05469893·Phase 2·Recruiting·Listed Jul 2022

Apply to this trial

A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation

for Acute Myeloid Leukemia

2 locations in Boston

Sponsor: Dana-Farber Cancer Institute

Sex: All·Age: 12+

Code: NCT04024761·Phase 1·Recruiting·Listed Jul 2019

Apply to this trial

IVIG for Infection Prevention After CAR-T-Cell Therapy

for Hematologic Malignancies

Sites in Boston +6 more locations

Sponsor: Fred Hutchinson Cancer Center

Sex: All·Age: 18+

Code: NCT05952804·Phase 2·Recruiting·Listed Jul 2023

Apply to this trial

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

for Acute Myeloid Leukemia

Sites in Boston +18 more locations

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06484062·Phase 1·Recruiting·Listed Jul 2024

Apply to this trial

Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

for Acute Myeloid Leukemia

2 locations in Boston

Sponsor: Dana-Farber Cancer Institute

Sex: All·Age: 18+

Code: NCT06138587·Phase 1·Recruiting·Listed Nov 2023

Apply to this trial

Epcoritamab and Rituximab for First-line Follicular Lymphoma

for Follicular Lymphoma

Drug: Epcoritamab

Sites in Boston +5 more locations

Sponsor: Reid Merryman, MD

Sex: All·Age: 18+

Code: NCT05783609·Phase 2·Recruiting·Listed Mar 2023

Apply to this trial

A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

for Multiple Myeloma

Drug: Elranatamab

2 locations in Boston

Sponsor: David Avigan

Sex: All·Age: 18+

Code: NCT06799026·Phase 1·Recruiting·Listed Jan 2025

Apply to this trial

Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing

for Acute Leukemia

1 location in Boston

Sponsor: Dana-Farber Cancer Institute

Sex: All·Age: 18+

Code: NCT06907797·Recruiting·Listed Apr 2025

Apply to this trial

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

for Monoclonal Gammopathy of Undetermined Significance (MGUS)

Sites in Boston, Brighton +5 more locations

Sponsor: Dana-Farber Cancer Institute

Sex: All·Age: 18+

Code: NCT02269592·Recruiting·Listed Oct 2014

Apply to this trial

Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

for Chronic Lymphocytic Leukemia

Drug: Venetoclax

3 locations in Boston

Sponsor: Massachusetts General Hospital

Sex: All·Age: 18+

Code: NCT04560322·Phase 2·Recruiting·Listed Sep 2020

Apply to this trial

Odronextamab in Low Tumor Volume Advanced FL

for Follicular Lymphoma

Drug: Odronextamab

1 location in Boston

Sponsor: Gottfried von Keudell, MD PhD

Sex: All·Age: 18+

Code: NCT07128641·Phase 2·Recruiting·Listed Aug 2025

Apply to this trial

Feasibility and Acceptability of Primary Palliative Care Intervention in Patients Undergoing Hematopoietic Stem Cell Transplantation

for Hematopoietic Cell Transplant

1 location in Boston

Sponsor: Massachusetts General Hospital

Sex: All·Age: 18+

Code: NCT06676852·Recruiting·Listed Nov 2024

Apply to this trial

Understanding Chronic Lymphocytic Leukemia

for Chronic Lymphocytic Leukemia

1 location in Boston

Sponsor: Dana-Farber Cancer Institute

Sex: All·Age: 18+

Code: NCT04028531·Recruiting·Listed Jul 2019

Apply to this trial

Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy

for Hematologic Malignancy

1 location in Boston

Sponsor: Massachusetts General Hospital

Sex: All·Age: 18+

Code: NCT05646576·Recruiting·Listed Dec 2022

Apply to this trial

Momelotinib During and After HCT in Myelofibrosis

for Myelofibrosis

1 location in Boston

Sponsor: Massachusetts General Hospital

Sex: All·Age: 18+

Code: NCT07104799·Phase 1·Recruiting·Listed Aug 2025

Apply to this trial

Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial

for Lymphoma

1 location in Boston

Sponsor: Dana-Farber Cancer Institute

Sex: All·Age: 18+

Code: NCT06923397·Recruiting·Listed Apr 2025

Apply to this trial

A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

for Acute Myeloid Leukemia

Drug: Venetoclax

Sites in Boston +3 more locations

Sponsor: M.D. Anderson Cancer Center

Sex: All·Age: 12+

Code: NCT06284486·Phase 1, Phase 2·Recruiting·Listed Feb 2024

Apply to this trial

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

for AML (Acute Myelogenous Leukemia)

Sites in Boston +12 more locations

Sponsor: Center for International Blood and Marrow Transplant Research

Sex: All·Age: 18 - 66

Code: NCT06859424·Phase 2·Recruiting·Listed Mar 2025

Apply to this trial

Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma

for Lymphoma

Drug: Venetoclax

1 location in Boston

Sponsor: Gottfried von Keudell, MD PhD

Sex: All·Age: 18+

Code: NCT06510309·Phase 2·Recruiting·Listed Jul 2024

Apply to this trial

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

for Acute Lymphoblastic Leukemia

Sites in Boston +2 more locations

Sponsor: City of Hope Medical Center

Sex: All·Age: 18 - 75·Accepts healthy volunteers

Code: NCT06059391·Phase 2·Recruiting·Listed Sep 2023

Apply to this trial

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

for Lymphoma

Drug: Glofitamab

Sites in Boston +2 more locations

Sponsor: Jennifer Crombie, MD

Sex: All·Age: 18+

Code: NCT05800366·Phase 2·Recruiting·Listed Apr 2023

Apply to this trial

Revumenib in Combination With 7+3 + Midostaurin in AML

for Acute Myeloid Leukemia

Drug: Revumenib

Sites in Boston +1 more location

Sponsor: Richard Stone, MD

Sex: All·Age: 18 - 75

Code: NCT06313437·Phase 1·Recruiting·Listed Mar 2024

Apply to this trial

A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

for Acute Myeloid Leukaemia (AML)

Drug: Venetoclax

2 locations in Boston

Sponsor: Jacqueline Garcia, MD

Sex: All·Age: 18+

Code: NCT07148180·Phase 1, Phase 2·Recruiting·Listed Aug 2025

Apply to this trial

BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma

for Mantle Cell Lymphoma

Drug: Sonrotoclax

Sites in Boston +5 more locations

Sponsor: Christine Ryan

Sex: All·Age: 18+

Code: NCT06854003·Phase 2·Recruiting·Listed Mar 2025

Apply to this trial

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

for Non-hodgkin Lymphoma

1 location in Boston

Sponsor: Marcela V. Maus, M.D.,Ph.D.

Sex: All·Age: 18+

Code: NCT06026319·Phase 1·Recruiting·Listed Sep 2023

Apply to this trial

Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia

for Chronic Lymphocytic Leukemia

Sites in Boston +3 more locations

Sponsor: Inhye Ahn

Sex: All·Age: 18+

Code: NCT06333262·Phase 2·Recruiting·Listed Mar 2024

Apply to this trial

Avo In R/R And Previously Untreated MCL

for Mantle Cell Lymphoma

Sites in Boston +2 more locations

Sponsor: Austin I Kim

Sex: All·Age: 18+

Code: NCT04855695·Phase 1, Phase 2·Recruiting·Listed Apr 2021

Apply to this trial

Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL

for Lymphoma

2 locations in Boston

Sponsor: Dana-Farber Cancer Institute

Sex: All·Age: 18+

Code: NCT06475235·Phase 1·Recruiting·Listed Jun 2024

Apply to this trial

Epco, Zanu, Ritux for R/R FL or MZL

for Follicular Lymphoma

Sites in Boston +2 more locations

Sponsor: Reid Merryman, MD

Sex: All·Age: 18+

Code: NCT06563596·Phase 2·Recruiting·Listed Aug 2024

Apply to this trial

Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)

for Leukemia

Drug: Venetoclax

1 location in Boston

Sponsor: Jennifer R. Brown, MD, PhD

Sex: All·Age: 18+

Code: NCT06644183·Phase 1, Phase 2·Recruiting·Listed Oct 2024

Apply to this trial

CONFIRM: Magnetic Resonance Guided Radiation Therapy

for Gastric Cancer

2 locations in Boston

Sponsor: Brigham and Women's Hospital

Sex: All·Age: 18+

Code: NCT04368702·Recruiting·Listed Apr 2020

Apply to this trial

Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

for Multiple Myeloma

2 locations in Boston

Sponsor: Dana-Farber Cancer Institute

Sex: All·Age: 18+

Code: NCT05706766·Recruiting·Listed Jan 2023

Apply to this trial

Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma

for Relapsed Cancer

2 locations in Boston

Sponsor: Massachusetts General Hospital

Sex: All·Age: 18+

Code: NCT05922501·Phase 2·Recruiting·Listed Jun 2023

Apply to this trial

Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

for Myeloma

Drug: Iberdomide

3 locations in Boston

Sponsor: Omar Nadeem, MD

Sex: All·Age: 18+

Code: NCT06518551·Phase 1, Phase 2·Recruiting·Listed Jul 2024

Apply to this trial

Mosunetuzumab for CLL MRD Clearance

for Leukemia

Drug: Mosunetuzumab

2 locations in Boston

Sponsor: Inhye Ahn

Sex: All·Age: 18+

Code: NCT07052695·Phase 1, Phase 2·Recruiting·Listed Jul 2025

Apply to this trial

Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation

for Chronic Lymphocytic Leukemia

Drug: Polatuzumab Vedotin

Sites in Boston +4 more locations

Sponsor: Christine Ryan

Sex: All·Age: 18+

Code: NCT06043674·Phase 2·Recruiting·Listed Sep 2023

Apply to this trial

Collection of Samples and Clinical Data From Patients With Amyloid Diseases

for Multiple Myeloma

1 location in Boston

Sponsor: Boston Medical Center

Sex: All·Age: 18+

Code: NCT00898235·Recruiting·Listed May 2009

Apply to this trial

Conditions in Blood cancer (Boston, MA)

Acute myeloid leukemia (AML)· 35 Non-Hodgkin lymphoma· 33 Multiple myeloma· 30 Chronic lymphocytic leukemia (CLL)· 21 Leukemia (other)· 19 Myelodysplastic syndromes (MDS)· 19 Hematologic malignancy· 16 Follicular lymphoma· 11 Small lymphocytic lymphoma· 11 Myelofibrosis· 10 Diffuse large B-cell lymphoma (DLBCL)· 10 Mantle cell lymphoma· 8 Myeloproliferative neoplasm· 7 Acute lymphoblastic leukemia· 6 Hodgkin lymphoma· 6 Marginal zone lymphoma· 5 Chronic myelomonocytic leukemia· 3 Burkitt lymphoma· 2